A Case of Autosomal Dominant Polycystic Kidney Disease with Emphysematous Polycystic Renal Infection That Required Surgical Treatment

Kentaro Watanabe¹, Teruhiro Fujiı¹, Shiho Makabe¹, Haruno Nakajima¹, Masayo Sato¹, Hiroshi Kataoka¹,², Ken Tsuchiya³, Kosaku Nitta¹ and Toshio Mochizuki¹,²

Abstract:
We encountered a patient with autosomal dominant polycystic kidney disease (ADPKD) complicated with emphysematous polycystic renal infection (EPRI). A 44-year-old woman visited our hospital for a fever, appetite loss, and gross hematuria. Because the patient was suffering from end-stage renal disease (ESRD), she was immediately hospitalized for hemodialysis. Multiple emphysematous infected cysts were noted in the right kidney, and antibiotic therapy and three rounds of cystic drainage were performed. However, the patient did not respond to treatment. Therefore, laparoscopic right nephrectomy was performed. ADPKD with comorbid EPRI is unresponsive to conservative treatment, and we believe that nephrectomy should be considered.

Key words: autosomal dominant polycystic kidney disease (ADPKD), cystic infection, emphysematous pyelonephritis, emphysematous polycystic renal infection, nephrectomy

Intern Med Advance Publication
(DOI: 10.2169/internalmedicine.1257-18)

Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease in which proliferating multiple cysts in the kidneys and liver can develop. In ADPKD, cystic infection is a common complication. However, ADPKD patients develop emphysematous infections in rare cases and may require urgent nephrectomy. In general, most emphysematous infections are emphysematous pyelonephritis (EPN). Gas production in the renal parenchyma and around the kidney is noted. It becomes severe in some cases, and the mortality rate is high (13.5%) (1). A number of EPN cases associated with ADPKD have been reported (2-12). In addition, cases of emphysematous polycystic renal infection (EPRI) associated with comorbid emphysematous infections of ADPKD, in which gas production within the cysts is observed, have been reported (13-17).

We herein report a case of ADPKD with a comorbid EPRI that required surgical treatment.

Case Report
A 44-year-old woman who had a family history of ADPKD (mother) first visited our hospital in 2008 to undergo a detailed examination for back pain and gross hematuria. Abdominal ultrasonography showed multiple bilateral renal cysts, and the patient was diagnosed with ADPKD based on these findings and her family history. In 2013, her serum creatinine level was 1.8 mg/dL. Thereafter, she discontinued hospital visits of her own accord. In July 2016, she visited our hospital due to a fever, loss of appetite, and gross hematuria. Laboratory findings showed an elevated white blood cell count (WBC: 25,680/µL), strongly positive C-reactive protein (CRP: 12.3 mg/dL) and advanced renal failure (blood urea nitrogen 218 mg/dL, serum creatinine
The patient was immediately admitted for a further examination and treatment for end-stage renal disease (ESRD) and suspected cystic infection.

The clinical course after admission is shown in Fig. 1. On admission, the patient was highly obese with a body mass index (BMI) of 34.2 kg/m². However, her HbA1c was 5.4%, and the patient had no history of diabetes mellitus. Her blood pressure was 112/81 mmHg, heart beat 101/min, and body temperature 36°C. The palpebral conjunctiva was pale, and the abdomen was distended, but there was no tenderness, back pain, or knocking pain. Mild edema was noted in her lower legs.

Since the laboratory findings depicted a state of ESRD with severe azotemia, hyperkalemia, and metabolic acidosis on admission, hemodialysis was emergently started. Ciprofloxacin was started because of the suspicion of cystic infection. On the third hospital day, abdominal computed tomography (CT) showed that the cysts on the upper pole of the right kidney were poorly defined and gaseous with opacity in the surrounding fat tissue and peritoneal thickening (Fig. 2A). The patient was diagnosed with EPRI. Therefore, ciprofloxacin was changed to meropenem. On the ninth hospital day, the cysts were less gaseous, but wall thickening and elevated adipose concentration were indicated on abdominal contrast-enhanced CT, suggesting that some infected cysts remained (Fig. 2B). Echography-guided drainage was performed. On the 13th hospital day, CT-guided drainage was performed. On the 15th hospital day, meropenem was changed to cefazolin, because drug eruption appeared that might have been caused by meropenem and because Escherichia coli detected in the drained fluid showed antimicrobial susceptibility to cefazolin. Since magnetic resonance imaging (MRI) on the 18th hospital day showed that infected cysts yet remained (Fig. 2C), CT-guided drainage was again performed on the 21st hospital day. Drainage was performed three times in total.

There were no positive bacteria on any cultures, including those for blood, urine, and fluid from drainage. The patient continued to suffer from a fever of 37.5°C or higher, and her CRP levels increased again. Cefazolin was changed to ceftriaxone. MRI on the 35th hospital day showed that there infected cysts yet remained compared to MRI on the 18th hospital day (Fig. 2D). We therefore decided that the patient could not be treated with antimicrobial agents and drainage alone and planned nephrectomy. However, the patient hesitated to undergo surgery, so we continued antibiotics with ceftriaxone. Although the CRP levels decreased to 2 mg/dL, the patient continued to suffer from a fever of 37°C or higher. Therefore, with her informed consent, we performed laparoscopic right nephrectomy on the 56th hospital day. After surgery, the fever immediately subsided, and both the WBC and CRP normalized. The patient was discharged on the 88th hospital day.
and *Klebsiella pneumoniae* have been reported as etiological factors, while insufficient blood flow, and an impaired immune function due to ESRD, cysts with high intracystic glucose levels may be an etiological factor (19). More specifically, similar to EPN, the causative bacteria may be drawn to areas with high tissue glucose levels, and areas with high glucose levels within the cysts may become infected as well. Regarding the treatment of EPRI, three out of five cases underwent urgent or elective nephrectomy, and the mortality rate is noted within the cysts, have also been reported as a comorbid emphysematous infection of ADPKD (13-17) (Table 1B). EPN presents with imaging findings of gas within the parenchyma, while EPRI presents with imaging findings of gas within cysts. Table 2 shows a comparison between comorbid EPN and EPRI of ADPKD. In both cases, the incidence is lower among women than with common EPN. Furthermore, most EPN patients are diabetic. Increased tissue glucose levels are believed to play a role in the mechanism of onset. However, a characteristic of EPRI is that the patients had no comorbid diabetes, and all were suffering from ESRD, with only one side of the kidneys affected in all patients. In addition to an impaired immune function due to ESRD, cysts with high intracystic glucose levels may be an etiological factor (19). More specifically, similar to EPN, the causative bacteria may be drawn to areas with high tissue glucose levels, and areas with high glucose levels within the cysts may become infected as well. Regarding the treatment of EPRI, three out of five cases underwent urgent or elective nephrectomy, and the mortality

**Discussion**

Generally, emphysematous infection in the kidney in which gas production is noted in the renal parenchyma is EPN (1). Regarding the patient background in EPN, the incidence is higher in women (male-to-female ratio =1:6) and more prevalent in Asian countries. It has been reported that 95% of EPN patients are diabetic, 25%-40% suffer from comorbid urinary tract obstruction, and neurogenic bladder is also considered a risk factor. Elevated tissue glucose levels, insufficient blood flow, and an impaired immune function have been reported as etiological factors, while *E. coli* and *Klebsiella pneumoniae*, among others, have been reported as causative bacteria (18). Regarding treatment, Ubee et al. reported that, although conservative treatment with antimicrobial agents or PCD is effective in most cases, some cases may require nephrectomy (1).

In ADPKD, 11 cases of EPN have been reported (2-12) (Table 1A). In addition, five cases of EPRI, in which gas production is noted within the cysts, have also been reported as a comorbid emphysematous infection of ADPKD (13-17) (Table 1B). EPN presents with imaging findings of gas within the parenchyma, while EPRI presents with imaging findings of gas within cysts. Table 2 shows a comparison between comorbid EPN and EPRI of ADPKD. In both cases, the incidence is lower among women than with common EPN. Furthermore, most EPN patients are diabetic. Increased tissue glucose levels are believed to play a role in the mechanism of onset. However, a characteristic of EPRI is that the patients had no comorbid diabetes, and all were suffering from ESRD, with only one side of the kidneys affected in all patients. In addition to an impaired immune function due to ESRD, cysts with high intracystic glucose levels may be an etiological factor (19). More specifically, similar to EPN, the causative bacteria may be drawn to areas with high tissue glucose levels, and areas with high glucose levels within the cysts may become infected as well. Regarding the treatment of EPRI, three out of five cases underwent urgent or elective nephrectomy, and the mortality
In conclusion, ADPKD with concurrent EPRI is resistant to conservative treatment compared to common EPN, and we believe nephrectomy should be considered as soon as possible after nephrectomy. In the present study, one case died despite conservative treatment, but the patient's condition improved after nephrectomy.

**Table 1.**

(A) Case reports of emphysematous pyelonephritis (EPN)

<table>
<thead>
<tr>
<th>Age</th>
<th>Sex</th>
<th>DM</th>
<th>Renal function</th>
<th>Laterality</th>
<th>Gas within the cyst</th>
<th>Gas within the parenchyma</th>
<th>Bacteria</th>
<th>Drainage</th>
<th>Urgent nephrectomy</th>
<th>Nephrectomy</th>
<th>Outcome</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>47</td>
<td>F</td>
<td>Unknown</td>
<td>Right</td>
<td>-</td>
<td>+</td>
<td>E.coli</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>recover</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>51</td>
<td>M</td>
<td>+</td>
<td>HD</td>
<td>Bilateral</td>
<td>-</td>
<td>E.coli</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>recover</td>
<td>3</td>
</tr>
<tr>
<td>3</td>
<td>50</td>
<td>F</td>
<td>+</td>
<td>Unknown</td>
<td>Bilateral</td>
<td>Unknown</td>
<td>Unknown</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>recover</td>
<td>4</td>
</tr>
<tr>
<td>4</td>
<td>64</td>
<td>M</td>
<td>+</td>
<td>Cr 5.9 mg/dL</td>
<td>Bilateral</td>
<td>Unknown</td>
<td>E.coli</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>recover</td>
<td>5</td>
</tr>
<tr>
<td>5</td>
<td>44</td>
<td>M</td>
<td>+</td>
<td>Cr 2.9 mg/dL</td>
<td>Left</td>
<td>Unknown</td>
<td>E.coli</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>recover</td>
<td>6</td>
</tr>
<tr>
<td>6</td>
<td>51</td>
<td>F</td>
<td>+</td>
<td>Cr 3.1 mg/dL</td>
<td>Right</td>
<td>+</td>
<td>Unknown</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>recover</td>
<td>7</td>
</tr>
<tr>
<td>7</td>
<td>76</td>
<td>F</td>
<td>+</td>
<td>PD</td>
<td>Right</td>
<td>-</td>
<td>E.coli</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>recover</td>
<td>8</td>
</tr>
<tr>
<td>8</td>
<td>42</td>
<td>M</td>
<td>+</td>
<td>Post transplant</td>
<td>Bilateral</td>
<td>E.coli</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>recover</td>
<td>9</td>
</tr>
<tr>
<td>9</td>
<td>43</td>
<td>M</td>
<td>-</td>
<td>HD</td>
<td>Bilateral</td>
<td>E.coli</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>recover</td>
<td>10</td>
</tr>
<tr>
<td>10</td>
<td>51</td>
<td>M</td>
<td>-</td>
<td>HD</td>
<td>Right</td>
<td>E.coli</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>recover</td>
<td>11</td>
</tr>
<tr>
<td>11</td>
<td>57</td>
<td>M</td>
<td>+</td>
<td>Cr 1.3 mg/dL</td>
<td>Bilateral</td>
<td>E.coli</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>recover</td>
<td>12</td>
</tr>
</tbody>
</table>

(B) Case reports of emphysematous polycystic renal infection (EPRI)

<table>
<thead>
<tr>
<th>Age</th>
<th>Sex</th>
<th>DM</th>
<th>Renal function</th>
<th>Laterality</th>
<th>Gas within the cyst</th>
<th>Gas within the parenchyma</th>
<th>Bacteria</th>
<th>Drainage</th>
<th>Urgent nephrectomy</th>
<th>Nephrectomy</th>
<th>Outcome</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>65</td>
<td>F</td>
<td>Unknown</td>
<td>Right</td>
<td>+</td>
<td>-</td>
<td>Clostridium perfringens</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>recover</td>
<td>13</td>
</tr>
<tr>
<td>2</td>
<td>40</td>
<td>M</td>
<td>Unknown</td>
<td>HD</td>
<td>Right</td>
<td>-</td>
<td>Unknown</td>
<td>-</td>
<td>+</td>
<td>death</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>57</td>
<td>M</td>
<td>-</td>
<td>ESRD</td>
<td>Right</td>
<td>-</td>
<td>E.coli</td>
<td>-</td>
<td>+</td>
<td>death</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>62</td>
<td>F</td>
<td>-</td>
<td>HD</td>
<td>Right</td>
<td>-</td>
<td>E.coli</td>
<td>+</td>
<td>-</td>
<td>recovery</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>61</td>
<td>M</td>
<td>-</td>
<td>PD</td>
<td>Left</td>
<td>-</td>
<td>Klebsiella pneumoniae</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>recovery</td>
<td>17</td>
</tr>
<tr>
<td>6</td>
<td>44</td>
<td>F</td>
<td>-</td>
<td>ESRD</td>
<td>Right</td>
<td>+</td>
<td>E.coli</td>
<td>+</td>
<td>-</td>
<td>recover</td>
<td>Present study</td>
<td></td>
</tr>
</tbody>
</table>

DM: Diabetes mellitus, HD: Hemodialysis, ESRD: End stage renal disease, PD: Peritoneal Dialysis, E.coli: Escherichia coli
Table 2. Comparison between EPN and EPRI
Complicated with ADPKD

<table>
<thead>
<tr>
<th></th>
<th>EPN</th>
<th>EPRI</th>
</tr>
</thead>
<tbody>
<tr>
<td>mean age (year)</td>
<td>52.4</td>
<td>54.8</td>
</tr>
<tr>
<td>female</td>
<td>4/11 (36%)</td>
<td>3/6 (50%)</td>
</tr>
<tr>
<td>DM</td>
<td>8/10 (80%)</td>
<td>0/4 (0%)</td>
</tr>
<tr>
<td>ESRD</td>
<td>5/11 (45%)</td>
<td>6/6 (100%)</td>
</tr>
<tr>
<td>bilateral</td>
<td>6/11 (55%)</td>
<td>0/6 (0%)</td>
</tr>
<tr>
<td>gas in the cysts</td>
<td>3/10 (30%)</td>
<td>6/6 (100%)</td>
</tr>
<tr>
<td>gas in the parenchyma</td>
<td>10/10 (100%)</td>
<td>0/6 (0%)</td>
</tr>
<tr>
<td>E.coli</td>
<td>9/11 (82%)</td>
<td>3/6 (50%)</td>
</tr>
<tr>
<td>drainage</td>
<td>2/11 (18%)</td>
<td>2/6 (33%)</td>
</tr>
<tr>
<td>urgent nephrectomy</td>
<td>2/11 (18%)</td>
<td>3/6 (50%)</td>
</tr>
<tr>
<td>nephrectomy</td>
<td>7/11 (64%)</td>
<td>4/6 (67%)</td>
</tr>
<tr>
<td>death</td>
<td>0/11 (0%)</td>
<td>2/6 (33%)</td>
</tr>
</tbody>
</table>

EPN: emphysematous pyelonephritis, DM: Diabetes mellitus, EPRI: emphysematous polycystic renal infection DM: Diabetes mellitus, ESRD: End stage renal disease, E.coli: Escherichia coli

Ethical approval

All procedures performed in the patient study were in accordance with the 1964 Declaration of Helsinki and its later amendments or with comparable ethical standards.

Informed consent

Informed consent was obtained from the patient.

References


The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).